Close Menu

NEW YORK (GenomeWeb) – Myriad Genetics reported after the close of the market on Tuesday that its fiscal fourth quarter revenues rose 1 percent year over year, thanks largely to a 6 percent increase in pharmaceutical and clinical service revenues, which offset flat molecular diagnostic testing revenues.

For the three months ended June 30, the firm reported total revenues of $200.9 million, up from $199.6 million in fiscal Q4 2017, and beating the consensus Wall Street estimate of $195.8 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.